Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $2.3 million.

  • ImmunoTech's Cash & Equivalents rose 15650.27% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 15650.27%. This contributed to the annual value of $1.7 million for FY2024, which is 6872.59% down from last year.
  • As of Q3 2025, ImmunoTech's Cash & Equivalents stood at $2.3 million, which was up 15650.27% from $476000.0 recorded in Q2 2025.
  • Over the past 5 years, ImmunoTech's Cash & Equivalents peaked at $21.0 million during Q2 2023, and registered a low of $476000.0 during Q2 2025.
  • In the last 3 years, ImmunoTech's Cash & Equivalents had a median value of $2.8 million in 2024 and averaged $5.5 million.
  • In the last 5 years, ImmunoTech's Cash & Equivalents plummeted by 9400.55% in 2024 and then skyrocketed by 15650.27% in 2025.
  • Quarter analysis of 3 years shows ImmunoTech's Cash & Equivalents stood at $5.4 million in 2023, then plummeted by 68.73% to $1.7 million in 2024, then soared by 37.98% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $476000.0 for Q2 2025, and $898000.0 during Q1 2025.